Chemokines are a family of chemotactic cytokines that direct the traffic of leukocytes and other cells in the body. Chemokines bind to G protein-coupled receptors (GPCRs) expressed on the surface of target cells to initiate intracellular signaling cascades and induce chemotaxis.
Although most chemokines have identified receptors, a few chemokines including CXCL17 are classified as “orphans” because the corresponding receptor still remains unknown.
Chemokine receptors represent very compelling drug targets because they participate in many different physiological processes and are often involved in the pathogenesis of various diseases.
Researchers at the University of California, Irvine, have identified the specific receptor for chemokine CXCL17. The discovery of this novel receptor, known as CXCR8, permits the researchers to investigate the mode of binding and, ultimately, disrupting this critical interaction to overcome various diseases and conditions, such as, gastrointestinal, respiratory, metabolic, infectious and oncologic disorders. It is further believed that evaluating this specific interaction will probe disorders in the lung or digestive system inflammatory diseases, such as, Crohn’s disease, ulcerative colitis, irritable bowel syndrome, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, chronic obstructive pulmonary disease, asthma, etc...
Scientifically, it is believed that the interaction of CXCL17 and CXCR8 controls the recruitment of macrophages and dendritic cells to sites of inflammation, especially, in the lung and digestive system. Therefore, by interfering with this interaction, the recruitment of macrophages to the site of inflammation is reduced, thereby alter the course of chronic human disease. The potential use of either agonists or antagonists including antibody to this chemokine-receptor interaction will further modulate inflammation and shed light on the potential clues towards designing functional and selective ligands in the treatment of chemokine-related diseases.
The invention is useful for developing novel approaches aimed at treating lung or digestive system inflammatory diseases, such as, Crohn’s disease, ulcerative colitis, irritable bowel syndrome, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, chronic obstructive pulmonary disease, asthma, etc...
|United States Of America||Published Application||20160368995||12/22/2016||2013-724|